[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@DrChoueiri](/creator/twitter/DrChoueiri)
"A tour-de-force articulate presentation from @MarcMachaalani: microbiome-linked sMAdCAM-1 stands up in X trials higher baseline better PFS (HR 0.75) & OS (HR 0.59); increase by C3 response (OR 1.88). #ESMO25 #RCC @myESMO @Annals_Oncology @OncLive @OncoAlert"  
[X Link](https://x.com/DrChoueiri/status/1979827676576879068) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-19T08:31Z 42.9K followers, 2339 engagements


"A state-of-the-art session by @tompowles1 he truly put his heart into it. From EV+pembro transforming urothelial cancer to TROP2/TOPO1+PD-(L)1 combos showing high ORR in 1L TNBC NSCLC and Breast Cancer as well emerging data in GI & Gyn cancers. #ESMO25 #ADCs @myESMO @Annals_Oncology @OncoAlert @OncBrothers @DanaFarber"  
[X Link](https://x.com/DrChoueiri/status/1979499036194246977) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-18T10:45Z 42.9K followers, XXX engagements


"We have Italy Germany and the UK @myESMO #ESMO25 Presidential I. Come on down"  
[X Link](https://x.com/DrChoueiri/status/1979554762354819157) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-18T14:26Z 42.9K followers, XXX engagements


"Influential high-impact biomarker presentation by @DrRanaMcKay with LAG3 expression: LAG3-high tumors show inflamed RNA expression (PD-L1/CTLA4/TIGIT) and better early IO response; low LAG3 reduced real-world ORR & more PD across 1L IO. #ESMO25 #RCC @myESMO @Annals_Oncology @OncLive @OncoAlert @OncBrothers"  
[X Link](https://x.com/DrChoueiri/status/1979799086787096751) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-19T06:37Z 42.9K followers, 1310 engagements


"Head-to-head win presented by #ShunLu: ivonescimab+chemo beats tislelizumab+chemo in 1L squamous NSCLC: PFS XXXX vs XXX mo (HR XXXX p0.0001). Practice-informing; OS pending. #ESMO25 #NSCLC @myESMO @Annals_Oncology @OncoAlert @OncLive"  
[X Link](https://x.com/DrChoueiri/status/1979920993406615680) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-19T14:42Z 42.9K followers, 1358 engagements


"Patient-reported outcomes hold up in NIAGARA trial by @MichvdHeijden: periop durvalumab+NAC (Arm D) vs NAC alone (Arm C). No HRQoL detriment; TTDD trends longer with Arm D; GHS/QoL HR XXXX pain HR XXXX. EFS/OS gains without QoL cost. #ESMO25 @myESMO @Annals_Oncology @OncoAlert @OncLive @DanaFarber"  
[X Link](https://x.com/DrChoueiri/status/1979187138139697558) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-17T14:05Z 42.9K followers, 1646 engagements


"FGFR3 precision push by #AlexandraDrakaki in FORAGER-1 Ph.I: LY3866288 hits IC90 at XXX mg BID; ORR XX% at XXX mg (n=28) and XX% XXX mg (n=82). Combo with EV+pembro opening. #ESMO25 @myESMO @Annals_Oncology @OncLive @OncoAlert @DanaFarber"  
[X Link](https://x.com/DrChoueiri/status/1979189298571170036) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-17T14:14Z 42.9K followers, 3324 engagements


"ADC + PD-1/TIGIT signal by #SunYoungRha in TROPION-PanTumor03 Ph.II study: Dato-DXd+rilve in a/mUC: ORR XX% 1L XX% 2L; PFS NR (1L) XXXX mo (2L). G3 TRAEs XX% (1L)/39% (2L). Encouraging controllable toxicity. #ESMO25 @myESMO @ASCOpost @OncoAlert @OncLive @DanaFarber @Annals_Oncology"  
[X Link](https://x.com/DrChoueiri/status/1979190848085446850) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-17T14:20Z 42.9K followers, 1456 engagements


"Kidney-sparing challenge to RNU in DISTINC-I trial Ph.II presented by #JiweiHuang : DV+tislelizumab + endoscopic/segmental surgery: cCR XXXX% (3 mo) 1-y kidney-intact EFS 68.4%; no G3 systemic tox. Biomarker: HER2 overexpression 3+/2+ in 42%. #ESMO25 @myESMO @Annals_Oncology @OncoAlert @OncLive @DanaFarber"  
[X Link](https://x.com/DrChoueiri/status/1979201788302516649) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-17T15:04Z 42.9K followers, 1631 engagements


"@katy_beckermann insightful presentation showing adenosine A2a Rc Antag add-on that falls short in a Ph. Ib/II trial: Ipi/nivo+ciforadenant: ORR XX% mPFS XXX mo. No efficacy lift over IO benchmarks. #ESMO25 #RCC @myESMO @ASCOpost @OncoAlert @OncLive @Annals_Oncology"  
[X Link](https://x.com/DrChoueiri/status/1979206218389352536) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-17T15:21Z 42.9K followers, XXX engagements


"Promising adjuvant RCC moment by #JamesLarkin discussing RAMPART Ph.III trial: durvalumab +/- tremelimumab after nephrectomy. DFS HR XXXX (95% CI 0.45-0.93); p=0.009. Significant DFS HR XXXX in the high risk grp. #ESMO25 #RCC @myESMO @OncoAlert @OncLive @Annals_Oncology"  
[X Link](https://x.com/DrChoueiri/status/1979450311866749011) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-18T07:31Z 42.9K followers, 1149 engagements


"Novel and exciting data by @BernatzSimon AI-graded thymic health from baseline CT predicts IO outcomes pan-cancer. high vs low PFS HR 0.59; OS HR XXXX after adjustment. Signal consistent across PD-L1/TMB strata. Future host-specific IO-marker #ESMO25 #AI @myESMO @DanaFarber @harvardmed"  
[X Link](https://x.com/DrChoueiri/status/1979475533327966399) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-18T09:11Z 42.9K followers, XXX engagements


"Practice-shaping presidential caliber from @Prof_Nadia_H DESTINY-Breast11: neoadjuvant T-DXdTHP tops ddAC-THP on pCR XXXX% vs XXXX% (11.2% p=0.003). Early positive trend in EFS. #ESMO25 #BreastCancer @myESMO @Annals_Oncology @DanaFarber"  
[X Link](https://x.com/DrChoueiri/status/1979559687948509229) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-18T14:46Z 42.9K followers, 2895 engagements


"Landmark practice-changing readout delivered by #Charlesgayer shifting SOC. DESTINY-Breast05 Ph. III shows T-DXd beating T-DM1 post-neoadjuvant in high-risk HER2+ eBC (IDFS HR XXXX XX% CI 0.34-0.66 p 0.001). #ESMO25 #BreastCancer @myESMO @OncLive @OncoAlert @DanaFarber"  
[X Link](https://x.com/DrChoueiri/status/1979568135159283752) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-18T15:19Z 42.9K followers, 2637 engagements


"4th and final Practice-relevant win presidential for today by #NicolettaColombo. ENGOT-ov65/KEYNOTE-B96: pembro + weekly paclitaxel +/- bev improves PFS (8.3 vs XXX mo; HR 0.70) in platinum-resistant ovarian cancer and OS benefit in PD-L1 CPS1 (HR 0.76). #ESMO25 #OvarianCancer @myESMO @OncLive @Annals_Oncology @DanaFarber"  
[X Link](https://x.com/DrChoueiri/status/1979580404978827266) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-18T16:08Z 42.9K followers, 2566 engagements


"A state-of-the-art session by @tompowles1 he truly put his heart into it. From EV+pembro transforming urothelial cancer to TROP2/TOPO1+PD-(L)1 combos showing high ORR in 1L bladder cancer NSCLC and Breast Cancer as well emerging data in GI & Gyn cancers. #ESMO25 #ADCs @myESMO @Annals_Oncology @OncoAlert @OncBrothers @DanaFarber"  
[X Link](https://x.com/DrChoueiri/status/1979508739951509898) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-18T11:23Z 42.9K followers, 6892 engagements


"Practice shifting huge win by #JunGuo in HER2-expressing la/mUC: DV+toripalimab chemo: PFS XXXX vs XXX mo (HR 0.36) and OS XXXX vs XXXX mo (HR 0.54). Grade3 TRAE XX% vs 87%. #ESMO25 #BladderCancer @myESMO @Annals_Oncology @OncoAlert"  
[X Link](https://x.com/DrChoueiri/status/1979949205767721262) [@DrChoueiri](/creator/x/DrChoueiri) 2025-10-19T16:34Z 42.9K followers, 2151 engagements